You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Eye conditions

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations

  • Highly specialised technologies guidance
  • Reference number: HST11
  • Published:  09 October 2019
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final evaluation determination
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 149 KB)

    Published:
    09 October 2019

Final evaluation determination

  • Final evaluation determination

  • Final evaluation determination document (PDF 370 KB)

    Published:
    04 September 2019
  • Public committee slides (PDF 2.04 MB)

    Published:
    04 September 2019
  • Committee papers (PDF 7 MB)

    Published:
    04 September 2019

Invitation to participate

  • Final stakeholder list (PDF 219 KB)

    Published:
    03 December 2018
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 776 KB)

    Published:
    03 December 2018
  • Final scope (PDF 258 KB)

    Published:
    03 December 2018
  • Equality Impact Assessment (Guidance development) (PDF 176 KB)

    Published:
    03 December 2018

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

  • Draft scope pre referral (PDF 344 KB)

    Published:
    26 July 2017
  • Draft matrix pre referral (PDF 218 KB)

    Published:
    26 July 2017
Back to top